Selumetinib Paediatric NF1 Japan Study

Summary

This is a phase I open label study designed to evaluate the safety, tolerability, PK and efficacy of selumetinib in Japanese paediatric patients with neurofibromatosis type 1 and inoperable and symptomatic plexiform neurofibroma.

Timeline

Start

2020-08-31

Primary completion

2021-06-16

Completion

2023-03-24

Drugs

Indications